Although the optimal treatment strategy in oesophageal (food pipe) cancer has been the subject of research for several decades, overall outcomes are very poor, with a 5-year survival of 15%. In the UK there are 9100 new cases of oesophago-gastric cancer diagnosed and approximately 7925 deaths every year (Cancer Research UK Oct 2019). Oesophageal cancer is a strategic priority for CRUK and a serious health problem world-wide. Pre-surgery treatment consists of chemotherapy or chemoradiation, but the optimal treatment is unknown. ...

GO TO STUDY

This is a multicenter, open-label, active control extension study to assess the long-term safety and efficacy of tegoprubart compared with tacrolimus in the preservation of allograft function after kidney transplantation. To be eligible for participation in this study, participants must have completed a designated Parent study. Qualification for this open-label extension (OLE) study will be specified in the Parent study Protocol. Participants who discontinue treatment early or discontinue from the Parent study are not eligible for this OLE study AT-1501-K209. Prospective participants ...

GO TO STUDY

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery.

GO TO STUDY

Each year in the NHS more than 250,000 high risk patients contemplate major surgery. These patients are older and usually have chronic disease. One in three high risk patients who choose surgery will experience will experience medical complications leading to long-term decline in health and quality of life. Awareness of these long term risks is poor amongst both doctors and patient. Consequently, many high-risk patients do not receive the information they need to make an informed decision about surgery. Shared ...

GO TO STUDY

The overall aim is: Part 1: To determine the efficacy of Pola-Glofit as bridging treatment to CAR-T cell therapy in patients with relapsed or refractory large B cell lymphomas. Part 2: To determine the efficacy of Pola-Glofit in patients with relapsed or refractory large B cell lymphomas who have failed to achieve complete metabolic response,or progressed after CAR-T cell therapy. The primary endpoints are: Part 1: Overall response rate (ORR) (Complete Metabolic Response (CMR) and Partial Metabolic Response (PMR)) after Pola-Glofit but prior to ...

GO TO STUDY

Study type Multicentre,non-blinded,feasibility randomised controlled trial Aim Feasibility study to assess feasibility of progressing to a full scale trial to evaluate strategies for platelet transfusion in participants with thrombocytopaenia and cancer associated thrombus (CAT) receiving anticoagulation Primary objective To determine the feasibility of designing and recruiting to a full RCT of management in participants with acute cancer-associated thrombosis (developed within 14 days) and thrombocytopaenia. Secondary objectives To determine: • Additional feasibility measures,such as recruitment rate,reasons for non participation in eligible participants and withdrawal rates and participation barriers ...

GO TO STUDY

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of pegozafermin for the treatment of Stage 2 or 3 liver fibrosis in adult subjects with NASH (Noncirrhotic Nonalcoholic Steatohepatitis). The study is designed to assess the efficacy and safety of 2 dose regimens of pegozafermin, administered either weekly (QW) or once every 2 weeks (Q2W) in subjects with biopsy-confirmed NASH (NAFLD activity score [NAS] ≥ 4, fibrosis stage F2 or F3 [NASH CRN system]). Approximately 840 subjects will be randomized 1:1:1 ...

GO TO STUDY

This is a multicenter evaluation of seladelpar, administered as a once-daily oral capsule, in a randomized, double-blind, placebo-controlled, parallel-group study in subjects with PBC. This fixed-duration study (156 weeks) will randomize approximately 192 subjects across approximately 150 sites worldwide. The population to be studied is patients with PBC and compensated cirrhosis restricted to Child-Pugh (CP)-A or CP-B.

GO TO STUDY

This is a multi-national, randomized, double-blinded study to evaluate the safety and effectiveness of AVIM therapy in patients with uncontrolled hypertension with a previously implanted Medtronic Astra/Azure pacemaker. Over 500 participants will be recruited across 100 sites in UK, Europe and US. AVIM is an investigational therapy that can be added to a pacemaker to allow for specific settings that may help with the treatment of hypertension. The study will be performed in three phases, Screening/Run-In, Randomised double-blind and Randomised ...

GO TO STUDY

Follicular lymphoma (FL) is the most common low grade or slow growing blood cancer. It affects white blood cells called B lymphocytes. FL usually responds well to treatment, but advanced stage (disseminated disease) cannot yet be cured. More treatment is needed when the disease comes back (relapses). The aims of treatment are to control symptoms and delay relapse for as long as possible. For most people initial treatment controls FL for many years and life expectancy is near normal, but ...

GO TO STUDY